...
首页> 外文期刊>Molecular pharmacology. >A single glycine residue at the entrance to the first membrane-spanning domain of the gamma-aminobutyric acid type A receptor beta(2) subunit affects allosteric sensitivity to GABA and anesthetics.
【24h】

A single glycine residue at the entrance to the first membrane-spanning domain of the gamma-aminobutyric acid type A receptor beta(2) subunit affects allosteric sensitivity to GABA and anesthetics.

机译:γ-氨基丁酸A型受体beta(2)亚基的第一个跨膜域入口处的单个甘氨酸残基影响对GABA和麻醉药的变构敏感性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Site-directed mutagenesis of the gamma-aminobutyric acid type A (GABA(A)) receptor beta(2) subunit has demonstrated that conversion of a conserved glycine residue located at the entrance to the first transmembrane domain into the homologous rho(1) residue phenylalanine alters the modulating effects of four different i.v. anesthetics: pentobarbital, alphaxalone, etomidate, and propofol. Using the baculovirus expression system in Spodoptera frugiperda 9 cells, anesthetic-induced enhancement of [(3)H]muscimol and [(3)H]flunitrazepam binding in receptors containing the beta(2)(G219F) point mutation displayed a significantly reduced efficacy in modulation by all four i.v. anesthetics tested. Furthermore, GABA(A) receptors containing the alpha(1)(G223F) point mutation also significantly decreased the maximal effect of etomidate- and propofol-induced enhancement of ligand binding. Conversely, the homologous point mutation in rho(1) receptors (F261G) changed the i.v. anesthetic-insensitive receptor to confer anesthetic modulation of [(3)H]muscimol binding. Consistent with the binding, functional analysis of pentobarbital-enhanced GABA currents recorded with whole-cell patch clamp demonstrated the beta(2)(G219F) subunit mutation eliminated the potentiating effect of the anesthetic. Similarly, propofol-enhanced GABA currents were potentiated less in alpha(1)beta(2)(G219F)gamma(2) receptors than in alpha(1)beta(2)gamma(2) receptors. Although ligand binding displayed comparable K(D) values for muscimol among wild-type, alpha(1)beta(2)gamma(2), and mutant receptors, patch-clamp recordings showed that alpha(1)beta(2)(G219F)gamma(2) receptors had a significantly more potent response to GABA than did alpha(1)beta(2)gamma(2) or alpha(1)(G223F)beta(2)gamma(2). The alpha(1)beta(2)(G219F)gamma(2) receptors also were more sensitive to direct channel activation by pentobarbital and propofol in the absence of GABA. These results suggest that the first transmembrane glycine residue on the beta(2) subunit may be important for conformational or allosteric interactions of channel gating by both GABA and anesthetics.
机译:γ-氨基丁酸A型(GABA(A))受体beta(2)亚基的定点诱变已表明,位于第一个跨膜结构域入口处的保守甘氨酸残基转化为同源rho(1)残基苯丙氨酸改变了四种静脉输液的调节作用麻醉药:戊巴比妥,αxalone,依托咪酯和丙泊酚。在杆状夜蛾9细胞中使用杆状病毒表达系统,麻醉剂诱导的[(3)H]麝香酚和[(3)H]氟硝西m在包含β(2)(G219F)点突变的受体中的结合增强显示功效显着降低由所有四个iv调制麻醉药经过测试。此外,包含alpha(1)(G223F)点突变的GABA(A)受体也显着降低了依托咪酯和丙泊酚诱导的配体结合增强的最大作用。相反,rho(1)受体(F261G)中的同源点突变改变了静脉。麻醉药不敏感的受体,以赋予[(3)H] muscimol结合麻醉调节作用。与绑定一致,全细胞膜片钳记录的戊巴比妥增强的GABA电流的功能分析表明,β(2)(G219F)亚基突变消除了麻醉药的增强作用。类似地,丙泊酚增强的GABA电流在alpha(1)beta(2)(G219F)gamma(2)受体中的增强作用要小于alpha(1)beta(2)gamma(2)受体中的增强作用。虽然配体结合显示在野生型,alpha(1)beta(2)gamma(2)和突变体受体之间的麝香酚可比的K(D)值,膜片钳记录表明,alpha(1)beta(2)(G219F )gamma(2)受体对GABA的反应明显比alpha(1)beta(2)gamma(2)或alpha(1)(G223F)beta(2)gamma(2)强。在没有GABA的情况下,alpha(1)beta(2)(G219F)gamma(2)受体对戊巴比妥和异丙酚的直接通道激活也更敏感。这些结果表明,β(2)亚基上的第一个跨膜甘氨酸残基可能对GABA和麻醉药对通道门控的构象或变构相互作用很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号